English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine Healthcare & Pharm
云顶新耀"AI+创新药"第一股成港股18A黑马
Mar 10, 2025 18:09 HKT
World's Most Sleep-Deprived Nation Has a Gender Crisis: Why Singaporean Women Bear the Heaviest Burden
Mar 10, 2025 13:00 HKT
Everest Medicines Hits Three-Year High as AI+mRNA Pipeline Reshapes Valuation
Mar 07, 2025 19:30 HKT
雲頂新耀股價創3年新高 AI+mRNA賦能管線重塑估值
Mar 07, 2025 19:24 HKT
云顶新耀股价创3年新高 AI+mRNA赋能管线重塑估值
Mar 07, 2025 19:16 HKT
OrbusNeich Achieves Fourth Consecutive Year of Revenue Growth with Record High Revenue of US$164.1 Million and Net Profit of US$39.7 Million
Mar 07, 2025 18:40 HKT
業聚醫療連續四年實現收入增長 達1.64億美元創新高 純利達3,970萬美元 建議派發末期股息每股10港仙
Mar 07, 2025 18:28 HKT
业聚医疗连续四年实现收入增长 达1.64亿美元创新高 纯利达3,970万美元 建议派发末期股息每股10港仙
Mar 07, 2025 18:10 HKT
Micreos Pharmaceuticals 與生物製劑 CDMO Northway Biotech 合作推動其工程化內溶素療法製造計畫
Mar 04, 2025 23:00 HKT
Micreos Pharmaceuticals Partners With Biologics CDMO Northway Biotech for Its Engineered Endolysin Therapeutic Manufacturing Program
Mar 04, 2025 20:00 HKT
重磅發佈 - 君聖泰醫藥在JAMA Network Open發表熊去氧膽小檗鹼治療2型糖尿病的臨床2期研究數據 療效顯著 多重代謝獲益 市場前景廣闊
Mar 04, 2025 16:48 HKT
重磅发布 - 君圣泰医药在JAMA Network Open发表熊去氧胆小檗碱治疗2型糖尿病的临床2期研究数据 疗效显著 多重代谢获益 市场前景广阔
Mar 04, 2025 12:32 HKT
HighTide Therapeutics Announces Publication of Phase 2 Study of Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes Mellitus in JAMA Network Open
Mar 04, 2025 12:26 HKT
Hua Medicine Awarded Shanghai Innovative Enterprise Headquarters
Mar 03, 2025 14:50 HKT
華領醫藥榮獲上海市創新型企業總部授牌
Mar 03, 2025 13:55 HKT
华领医药荣获上海市创新型企业总部授牌
Mar 03, 2025 13:46 HKT
迪拜高层代表团一行参访君圣泰医药 解码中国医药创新范式
Feb 27, 2025 21:01 HKT
CGFNS International 將更名為 TruMerit
Feb 26, 2025 15:00 HKT
雲頂新耀發佈伊曲莫德(VELSIPITY(R))完整維持期數據 創新研發實力再獲認可
Feb 26, 2025 14:21 HKT
云顶新耀发布伊曲莫德(VELSIPITY(R))完整维持期数据 创新研发实力再获认可
Feb 26, 2025 14:18 HKT
<< Previous  Next >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: